Pharma Journalist -

BioMed X, an independent research institute that identifies big biomedical research challenges and provides innovative solutions by combining global crowdsourcing with local incubation,…
Read More...

Cipla Limited announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine…
Read More...

CytoAgents announced that it has been awarded a National Institutes of Health (NIH) grant to accelerate the development of its lead drug candidate, GP1681, an investigational new drug…
Read More...

Skyhawk Therapeutics, Inc. announced that it has expanded its strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and…
Read More...

Legend Biotech Corporation announced that Legend and Noile-Immune Biotech, Inc. have entered into a license agreement whereby Legend will have the right to develop CAR-T and/or TCR-T…
Read More...

Glenmark Pharmaceuticals, a research-led integrated global pharmaceutical company, has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received…
Read More...

Seattle Genetics, Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA (tucatinib) tablets in combination with trastuzumab and…
Read More...

Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s mRNA vaccine candidate (mRNA-1273) against the novel…
Read More...

The Phase 3 IKEMA clinical trial evaluating Sarclisa (isatuximab) added to carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis, demonstrating…
Read More...

London – On Wednesday, 27th May, OCT Virtual (https://arena-international.com/octvirtual/) will delve into challenges the clinical trials community is facing as the disruption from…
Read More...